ASPSCR1-TFE3 and LUC7L3-TFE3 fusion tumors had higher TFE3 activities, while featured lower kidney signature scores, than other fusion types of TFE3-tRCC (Fig. 5f). This evidence concerns the gene ASPSCR1 and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.